Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldose reductase inhibitor-diabetes complications trial (ADCT)

Trial Profile

Aldose reductase inhibitor-diabetes complications trial (ADCT)

Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2012

At a glance

  • Drugs Epalrestat (Primary)
  • Indications Diabetic nephropathies; Diabetic neuropathies
  • Focus Therapeutic Use
  • Acronyms ADCT
  • Most Recent Events

    • 01 Sep 2007 Results have been published in journal of Diabetes Research and Clinical Practice.
    • 21 Feb 2007 New trial record.
    • 01 Jun 2005 The primary endpoint has been met (Change from baseline in median motor nerve conduction velocity (MNCV) at 3 years) according to the results published at 65th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top